Summary:
Click image to enlargeResearchers at Skylight Health Research - Burlington are conducting a clinical trial to evaluate the efficacy and safety of an investigational vaccine called mRNA-1647 against CMV infection in healthy female adults ages 16 to 40.
Qualified Participants Must:
• Be a woman between 16-40 years of age
• Be in good health
• Be in close contact or anticipate having contact with at least one child 5 years of age or younger for at least 8 hours a week, if age 20 or older
• Not be pregnant or planning on becoming pregnant within the next 10 months
Qualified Participants May Receive:
There is no cost to participate and health insurance is not required to participate. Participants will receive all study-related visits and investigational vaccine or placebo at no cost. Eligible participants will receive compensation up to $2,078.00 total for completing the study based upon the number of visits completed.